L-NMMHA | 75830-53-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: L-NMMHA
• 英文别名: (2S)-2-amino-6-[(N'-methylcarbamimidoyl)amino]hexanoic acid
• CAS: 75830-53-4
• 化学式: C₈H₁₈N₄O₂
• 分子量: 202.257
• InChiKey: BISBENXUJVLWNC-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  114
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  溴化氰 、 L-赖氨酸 、 甲胺 生成 L-NMMHA
  参考文献：
  名称：

  Synthesis of guanidino-N-alkylarginines by the use of polymeric pseudoureas

  摘要：

  DOI：

  10.1021/jo00317a033

文献信息

• METASTIN DERIVATIVE AND USE THEREOF
  申请人：Asami Taiji

  公开号：US20110118172A1

  公开（公告）日：2011-05-19

  The invention provides a stable metastin derivative having excellent biological activities (a cancer metastasis-inhibiting activity, a cancer proliferation-inhibiting activity, a gonadotropin secretion-promoting activity, a sex hormone secretion-promoting activity, etc.). By replacing the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, the blood stability and solubility of the metastin derivative can be more improved, the gel tendency of the metastin derivative can be reduced, the pharmacokinetics of the metastin derivative can be improved, and the metastin derivative can exhibit an excellent cancer metastasis-inhibiting activity and cancer proliferation-inhibiting activity. The metastin derivative can also exhibit a gonadotropin secretion-inhibiting activity, a sex hormone secretion-inhibiting activity, etc.

  该发明提供了一种稳定的metastin衍生物，具有优秀的生物活性（如癌症转移抑制活性、癌细胞增殖抑制活性、促性腺激素分泌活性、促性激素分泌活性等）。通过将metastin的构成氨基酸替换为本发明的metastin衍生物中的特定氨基酸，可以进一步改善metastin衍生物的血液稳定性和溶解性，减少metastin衍生物的凝胶倾向，改善metastin衍生物的药代动力学，并使metastin衍生物表现出优秀的癌症转移抑制活性和癌细胞增殖抑制活性。metastin衍生物还可以表现出促性腺激素分泌抑制活性、促性激素分泌抑制活性等。
• EP2277900A1
  申请人：——

  公开号：EP2277900A1

  公开（公告）日：2011-01-26
• NOVEL INHIBITORS OF KALLIKREIN PROTEASES AND USES THEREOF
  申请人：Ecole Polytechnique Federale de Lausanne (EPFL)

  公开号：US20220267379A1

  公开（公告）日：2022-08-25

  The present invention relates to a cyclic inhibitor of a kallikrein protease comprising or consisting of (I) the peptide (X 1 (X 2 )(X 3 )R(X 4 )(X 5 )(X 6 )(X 7 )(X 8 )(X 9 )(X 10 )(X 11 ) (Formula (X)), wherein (X 1 ) is present or absent and, is preferably present, and if present, is an amino acid, and is most preferably D-alanine or G; (X 2 ) is an amino acid with a side chain; (X 3 ) is an amino acid with a polar uncharged side chain, is preferably with a polar uncharged side chain comprising a hydroxyl group, is more preferably T or S and is most preferably T; (X 4 ) is an amino acid, preferably citrulline, Q or E; (X 5 ) is an amino acid, preferably an amino acid with a hydrophobic side chain; (X 6 ) is present or absent, is preferably absent, and, if present, is an amino acid with a negatively charged side chain, preferably D; (X 7 ) is present or absent, is preferably present, and, if present, is an amino acid, more preferably an amino acid with a side chain comprising a pyrrole of indole, even more preferably P, hydroxyl-proline, (R)-3-piperidine carboxylic acid or W, and most preferably P; (X 8 ) is present or absent and, if present, is an amino acid, and is preferably absent; (X 9 ) is present or absent and, if present, is an amino acid, and is preferably absent; (X 10 ) is an amino acid with a side chain; and (X 11 ) is present or absent and, if present, is an amino acid, and is preferably absent; wherein the side chains of (X 2 ) and (X 10 ) are connected via a connecting molecule, said connecting molecule having at least two functional groups, each functional group forming a covalent bond with one of the side chains of (X 2 ) and (X 10 ); and wherein the kallikrein protease is Kallikrein-related peptidase (KLK5); or (II) the peptide (Y 1 )(Y 2 )(Y 3 ) (Y 4 )(Y 5 )(Y 6 )(Y 7 )(Y 8 )(Y 9 ) (Formula (Y)), wherein (Y 1 ) is present or absent, is preferably present, and, if present, is an amino acid, preferably P, L-beta-hydroxyl-proline, D-proline, (R)-3-piperidine carboxylic acid, Q or R, and is most preferably P; (Y 2 ) is an amino acid with a side chain; (Y 3 ) is I, L or L-Neopentylglycine, and is preferably L; (Y 4 ) is Y or F, and is preferably Y; (Y 5 ) is an amino acid, preferably an amino acid with a hydrophobic side chain, or Q or R, is more preferably L, norleucine, Q, I, R or M, and is most preferably norleucine or L; (Y 6 ) is an amino acid, preferably an amino acid with a hydrophobic side chain and is most preferably A; (Y 7 ) is absent or present, preferably present and, if present, is an amino acid preferably Q, homoarginine, 4-guanidino-phenlalanine or R; (Y 8 ) is an amino acid with a side chain; and (Y 9 ) is present or absent and, if present, is an amino acid, preferably S, and is most preferably absent; wherein the side chains of (Y 2 ) and (Y 8 ) are connected via a connecting molecule, said connecting molecule having at least two functional groups, each functional group forming a covalent bond with one of the side chains of (Y 2 ) and (Y 8 ); and wherein the kallikrein protease is Kallikrein-related peptidase 7 (KLK7).